Want to see INO full AI Analyst Report?
INO Stock Chart & Stats
$0.97
-$0.05(-4.89%)
At close: 4:00 PM EDT
$0.97
-$0.05(-4.89%)
Day’s Range― - ―
52-Week Range$0.56 - $2.98
Previous CloseN/A
Volume3.72M
Average Volume (3M)1.46M
Market Cap
$53.97M
Enterprise Value$91.25
Total Cash (Recent Filing)$37.68M
Total Debt (Recent Filing)$8.70M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 12, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,273,240
10 Day Avg. Volume1,420,987
30 Day Avg. Volume1,463,718
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.39
Price to Sales (P/S)1248.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.25Price Target Upside338.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress On INO-3107Acceptance of the BLA and a set PDUFA date materially reduces timing uncertainty and creates a defined regulatory path. Mid‑cycle review raised no new significant issues, which de‑risks near‑term approval probability and enables focused commercial and financing planning over the next 6–12 months.
Strong Phase I/II Efficacy And SafetyRobust clinical signals (large reductions in surgeries and favorable safety vs comparator) support a meaningful clinical benefit and a label comparable to incumbents. Durable efficacy and a differentiated safety profile improve commercial adoption prospects and strengthen confirmatory trial design.
Platform Partnerships And Pipeline DiversificationStrategic collaborations and a growing DPROT platform diversify risk beyond a single asset, bring external expertise and resources, and enhance long‑term optionality. Partnered programs and new indications can accelerate development, provide non‑dilutive funding or milestones, and build platform credibility.
Bears Say
High Cash Burn And Limited RunwaySustained quarterly burn and a runway only into Q1 2027 create ongoing funding pressure through a pivotal regulatory window. The persistent need to raise capital increases dilution risk, could force suboptimal financing terms, and distract management from commercialization and trial execution.
Near-zero Revenue And Persistent LossesLack of meaningful revenue means operations cannot be self‑funded; negative operating and free cash flow translate losses into real cash outflows. Until commercial sales materialize, the company is structurally dependent on external capital, increasing vulnerability to funding or market setbacks.
Balance Sheet Deterioration And Higher LeverageDebt exceeding equity in the TTM snapshot signals reduced financial flexibility and higher solvency risk. Elevated leverage raises financing costs, limits covenant‑free options, and could constrain the company's ability to fund confirmatory trials or a commercial launch without restrictive financing terms.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $0.56 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $53.97M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.07.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 82,273,240 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (338.14% Upside)
$4.25 (338.14% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-42.96%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. (INO) is a biotechnology company focused on developing DNA-based medicines and vaccines, primarily in oncology and infectious diseases. The company’s development work centers on its proprietary DNA plasmid technology and related delivery approach, advancing product candidates through clinical development rather than marketing a broad portfolio of commercialized products.
INO Company Deck
INO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$4.25
▲(338.14% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
14.81% Mutual Funds
0.04% Other Institutional Investors
79.90% Public Companies and
Individual Investors